Serveur d'exploration Tocilizumab - Checkpoint (PubMed)

Index « Mesh.i » - entrée « Drug Substitution »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Drug Resistant Epilepsy < Drug Substitution < Drug Synergism  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 45.
[0-20] [0 - 20][0 - 45][20-40]
Ident.Authors (with country if any)Title
000260 (2019) Nienke M. Ter Haar [Pays-Bas] ; E H Pieter Van Dijkhuizen [Pays-Bas] ; Joost F. Swart [Pays-Bas] ; Annet Van Royen-Kerkhof [Pays-Bas] ; Ayman El Idrissi [Pays-Bas] ; Arjen P. Leek [Pays-Bas] ; Wilco De Jager [Pays-Bas] ; Mark C H. De Groot [Pays-Bas] ; Saskia Haitjema [Pays-Bas] ; Dirk Holzinger [Allemagne] ; Dirk Foell [Allemagne] ; Jorg Van Loosdregt [Pays-Bas] ; Nico M. Wulffraat [Pays-Bas] ; Sytze De Roock [Pays-Bas] ; Sebastiaan J. Vastert [Pays-Bas]Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.
000356 (2019) Kenji Oku [Japon] ; Tatsuya Atsumi [Japon]Rheumatology practice in Japan: challenges and opportunities.
000471 (2019) Andrea Rubbert-Roth [Suisse] ; Melinda Zsuzsanna Szab [Hongrie] ; Melinda Kedves [Hongrie] ; György Nagy [Hongrie] ; Fabiola Atzeni [Italie] ; Piercarlo Sarzi-Puttini [Italie]Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents.
000532 (2019) Katsuhiko Takabayashi [Japon] ; Fumihiko Ando [États-Unis] ; Takahiro Suzuki [Japon]Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data.
000652 (2018) Yuko Kaneko [Japon] ; Masaru Kato [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekara Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon]Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
000745 (2018) Thomas Frisell [Suède] ; Eva Baecklund [Suède] ; Karin Bengtsson [Suède] ; Daniela Di Giuseppe [Suède] ; Helena Forsblad-D'Elia [Suède] ; Johan Askling [Suède]Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
000774 (2018) Lisa Baganz [Allemagne] ; Adrian Richter [Allemagne] ; Jörn Kekow [Allemagne] ; Arnold Bussmann [Allemagne] ; Andreas Krause [Allemagne] ; Carsten Stille [Allemagne] ; Joachim Listing [Allemagne] ; Angela Zink [Allemagne] ; Anja Strangfeld [Allemagne]Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort.
000878 (2018) Tao Gu [États-Unis] ; Alex Mutebi ; Bradley S. Stolshek ; Hiangkiat TanCost of biologic treatment persistence or switching in rheumatoid arthritis.
000983 (2017) Ernest H. Choy [Royaume-Uni] ; Corrado Bernasconi [Suisse] ; Maher Aassi [Suisse] ; Jose Fernando Molina [Colombie] ; Oscar Massimiliano Epis [Italie]Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
000985 (2017) Wenhui Wei [États-Unis] ; Keith Knapp [États-Unis] ; Li Wang [États-Unis] ; Chieh-I Chen [États-Unis] ; Gary L. Craig [États-Unis] ; Karen Ferguson [États-Unis] ; Sergio Schwartzman [États-Unis]Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
000A45 (2017) Dong-Jin Park [Corée du Sud] ; Sung Jae Choi [Corée du Sud] ; Kichul Shin [Corée du Sud] ; Hyoun-Ah Kim [Corée du Sud] ; Yong-Beom Park [Corée du Sud] ; Seong Wook Kang [Corée du Sud] ; Seung-Ki Kwok [Corée du Sud] ; Seong-Kyu Kim [Corée du Sud] ; Eon Jeong Nam [Corée du Sud] ; Yoon-Kyoung Sung [Corée du Sud] ; Jaejoon Lee [Corée du Sud] ; Chang Hoon Lee [Corée du Sud] ; Chan Hong Jeon [Corée du Sud] ; Shin-Seok Lee [Corée du Sud]Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry.
000A99 (2017) Benjamin Chastek [États-Unis] ; Laura K. Becker [États-Unis] ; Chieh-I Chen [États-Unis] ; Puneet Mahajan [États-Unis] ; Jeffrey R. Curtis [États-Unis]Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
000B75 (2017) Josef S. Smolen [Autriche] ; Robert Landewé [Pays-Bas] ; Johannes Bijlsma [Pays-Bas] ; Gerd Burmester [Allemagne] ; Katerina Chatzidionysiou [Suède] ; Maxime Dougados [France] ; Jackie Nam [Royaume-Uni] ; Sofia Ramiro [Pays-Bas] ; Marieke Voshaar [Pays-Bas] ; Ronald Van Vollenhoven [Pays-Bas] ; Daniel Aletaha [Autriche] ; Martin Aringer [Allemagne] ; Maarten Boers [Pays-Bas] ; Chris D. Buckley [Royaume-Uni] ; Frank Buttgereit [Allemagne] ; Vivian Bykerk [États-Unis] ; Mario Cardiel [Mexique] ; Bernard Combe [France] ; Maurizio Cutolo [Italie] ; Yvonne Van Eijk-Hustings [Pays-Bas] ; Paul Emery [Pays-Bas] ; Axel Finckh [Suisse] ; Cem Gabay [Suisse] ; Juan Gomez-Reino [Espagne] ; Laure Gossec [France] ; Jacques-Eric Gottenberg [France] ; Johanna M W. Hazes [Pays-Bas] ; Tom Huizinga [Pays-Bas] ; Meghna Jani [Royaume-Uni] ; Dmitry Karateev [Russie] ; Marios Kouloumas [Suisse] ; Tore Kvien [Norvège] ; Zhanguo Li [République populaire de Chine] ; Xavier Mariette [France] ; Iain Mcinnes [Royaume-Uni] ; Eduardo Mysler [Argentine] ; Peter Nash [Australie] ; Karel Pavelka [République tchèque] ; Gyula Po R [Hongrie] ; Christophe Richez [France] ; Piet Van Riel [Pays-Bas] ; Andrea Rubbert-Roth [Allemagne] ; Kenneth Saag [États-Unis] ; Jose Da Silva [Portugal] ; Tanja Stamm [Autriche] ; Tsutomu Takeuchi [Japon] ; René Westhovens [Belgique] ; Maarten De Wit [Pays-Bas] ; Désirée Van Der Heijde [Pays-Bas]EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
000C08 (2017) Seoyoung C. Kim [États-Unis] ; Daniel H. Solomon [États-Unis] ; James R. Rogers [États-Unis] ; Sara Gale [États-Unis] ; Micki Klearman [États-Unis] ; Khaled Sarsour [États-Unis] ; Sebastian Schneeweiss [États-Unis]Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
000C67 (2016) Yutaka Kawahito[Guidelines for the management of rheumatoid arthritis].
000D84 (2016) Laisy Zacarías Martínez [Espagne] ; Lourdes Mateo Soria [Espagne] ; Míriam Ma Osa Círia [Espagne] ; Ariadna Clos Parals [Espagne] ; Eduard Cabré Gelada [Espagne] ; Eugeni Domènech Morral [Espagne]Poor correlation between acute phase reactants and intestinal involvement in patients with onset of Crohn's disease under treatment with an interleukin-6 inhibitor due to seronegative arthropathy.
000E37 (2016) Coline Faivre [France] ; Axel Patrice Villani [France] ; François Aubin [France] ; Dan Lipsker [France] ; Martine Bottaro [France] ; Jean-David Cohen [France] ; François Durupt [France] ; Géraldine Jeudy [France] ; Emilie Sbidian [France] ; Eric Toussirot [France] ; Valérie Badot [Belgique] ; Sébastien Barbarot [France] ; Sébastien Debarbieux [France] ; Emmanuel Delaporte [France] ; Guetty Goegebeur [France] ; Jacques Morel [France] ; Aude Nassif [France] ; Gérard Duru [France] ; Denis Jullien [France]Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
000E49 (2016) Lianne Kearsley-Fleet [Royaume-Uni] ; Rebecca Davies [Royaume-Uni] ; Eileen Baildam ; Michael W. Beresford ; Helen E. Foster ; Taunton R. Southwood [Royaume-Uni] ; Wendy Thomson [Royaume-Uni] ; Kimme L. Hyrich [Royaume-Uni]Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.
000E96 (2016) Yuko Kaneko [Japon] ; Tatsuya Atsumi [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekata Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Hayato Nagasawa [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon]Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
000E98 (2016) Tristan Pascart [France] ; Peggy Philippe [France] ; Elodie Drumez [France] ; Xavier Deprez [France] ; Bernard Cortet [France] ; Alain Duhamel [France] ; Eric Houvenagel [France] ; René-Marc Flipo [France]Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
000E99 (2016) Young Ho Lee [Corée du Sud] ; Sang-Cheol Bae [Corée du Sud]Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/Mesh.i -k "Drug Substitution" 
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/Mesh.i  \
                -Sk "Drug Substitution" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Drug Substitution
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021